Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Synthorx, Inc.    THOR

SYNTHORX, INC.

(THOR)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi ends research in diabetes, narrows units to spur profit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/09/2019 | 05:28pm EST
FILE PHOTO:  The logo of Sanofi is seen at the company's research and production centre in Vitry-sur-Seine,

Sanofi said on Monday it would end its research efforts in diabetes and cardiovascular diseases as part of a revamp that will narrow the number of its business units in the hope of bolstering growth and profit.

The French drugmaker, whose pipeline has disappointed investors in recent years, poached new chief executive Paul Hudson from Swiss pharma group Novartis in September to revitalise the company.

Its move to ditch diabetes research - announced alongside cost savings targets - marks a major turning point for a firm whose products dominated the insulin market for nearly two decades, before it was hit by patent losses and a drop in sales.

"We recognise it is getting more difficult to get breakthrough innovation and that we have to be efficient and move our resources to areas of opportunity, as tough a choice as that is," Hudson told reporters.

The firm is bulking up elsewhere, as in the lucrative field of cancer drugs. It announced a deal to buy U.S. biotechnology firm Synthorx for about $2.5 billion earlier on Monday.

Sanofi, which is due to further detail strategic plans to investors on Tuesday in Cambridge, Massachusetts, said it was targeting new cost savings of 2 billion euros (1.7 billion pounds) by 2022, by tightening spending and shaking up its supply chain.

It also aims for a core operating margin of 30% by then, up from 25.8% last year.

The group emphasized the potential for its eczema treatment Dupixent, recently approved in other therapeutic areas such as asthma, with an aim to expand sales to more than 10 billion euros.

Revenue for the drug, developed with U.S. partner Regeneron Pharmaceuticals Inc, was up 268% in 2018, reaching 788 million euros.

Sanofi, currently organised around five global business units, said it would rejig these around three pillars: specialty care, which includes oncology and rare diseases, as well as vaccines and general medicines.

Its consumer healthcare unit - known for over-the-counter products such as paracetamol Doliprane, erectile dysfunction drug Cialis and influenza treatment Tamiflu - will be considered as a standalone business, Sanofi said.

It would have its own operational dynamic, the firm added, though it did not clarify what this meant in the longer term.

Sources told Reuters last month that Sanofi was considering a joint venture or an outright sale among options for the division.

"Our objective for the consumer healthcare business is to unlock value and entrepreneurial energy by growing faster than the market over mid-term," Hudson said.

By Matthias Blamont

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS 1.26% 92.78 Delayed Quote.0.96%
REGENERON PHARMACEUTICALS 0.10% 385.94 Delayed Quote.2.79%
SANOFI 0.63% 92.19 Real-time Quote.2.87%
SYNTHORX, INC. -0.07% 68.03 Delayed Quote.-2.66%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SYNTHORX, INC.
2019Tesla gets Chinese boost, Boeing’s new troubles, scandal for Tesco…
2019WeissLaw LLP Investigates Synthorx, Inc.
PR
2019Monteverde & Associates PC Announces an Investigation of SYNTHORX, INC. - THO..
PR
2019SANOFI : to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Bi..
AQ
2019Sanofi shares rally on new margin goals, narrower drug focus
RE
2019Regeneron Shares Fall Premarket as Sanofi Signals Possible Stake Sale
DJ
2019Sanofi to Get Out of Diabetes Research -- WSJ
DJ
2019Merck, Sanofi Push To Add Cancer Drugs -- WSJ
DJ
2019Big Drugmakers Push Deeper Into Cancer Treatment -- 4th Update
DJ
2019Sanofi ends research in diabetes, narrows units to spur profit
RE
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -53,0 M
Net income 2019 -49,2 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -44,1x
P/E ratio 2020 -31,1x
Capi. / Sales2019 infx
Capi. / Sales2020 infx
Capitalization 2 176 M
Chart SYNTHORX, INC.
Duration : Period :
Synthorx, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNTHORX, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 68,00  $
Last Close Price 68,03  $
Spread / Highest target -0,04%
Spread / Average Target -0,04%
Spread / Lowest Target -0,04%
EPS Revisions
Managers
NameTitle
Laura K. Shawver President, Chief Executive Officer & Director
Pratik Shah Chairman
Tighe M. Reardon CFO & Principal Accounting Officer
Marcos Milla Chief Scientific Officer
Joseph Leveque Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SYNTHORX, INC.-2.66%2 176
IQVIA HOLDINGS INC.4.53%31 339
LONZA GROUP3.82%28 010
CELLTRION, INC.--.--%20 141
SEATTLE GENETICS, INC.-4.60%18 681
INCYTE CORPORATION-7.81%17 339